Assembly of the TLR2/6 transmembrane domains is essential for activation and is a target for prevention of sepsis

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6410-6422

  Fink, Avner ^a,b   Reuven, Eliran M ^a   Arnusch, Christopher J ^a,c   Shmuel Galia, Liraz ^a   Antonovsky, Niv ^a   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DIMERIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL MOUSE; FEMALE; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; OLIGOMERIZATION; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SEPSIS;

ANIMALS; CELL LINE; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; IMMUNOPRECIPITATION; MACROPHAGES; MICE; MICE, INBRED C57BL; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6;

EID: 84879099330     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202033     Document Type: Article

References (57)

1. Foster, S. L., and R. Medzhitov. 2009. Gene-specific control of the TLR-induced inflammatory response. Clin. Immunol. 130: 7-15.
2. Mitchell, J. A., M. J. Paul-Clark, G. W. Clarke, S. K. McMaster, and N. Cartwright. 2007. Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. J. Endocrinol. 193: 323-330. (Pubitemid 47028685)
3. O'Neill, L. A., and A. G. Bowie. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7: 353-364. (Pubitemid 46674493)
4. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554. (Pubitemid 36437931)
5. Meng, G., M. Rutz, M. Schiemann, J. Metzger, A. Grabiec, R. Schwandner, P. B. Luppa, F. Ebel, D. H. Busch, S. Bauer, et al. 2004. Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113: 1473-1481. (Pubitemid 39071703)
6. Feezor, R. J., C. Oberholzer, H. V. Baker, D. Novick, M. Rubinstein, L. L. Moldawer, J. Pribble, S. Souza, C. A. Dinarello,W. Ertel, and A. Oberholzer. 2003. Molecular characterization of the acute inflammatory response to infections with Gram-negative versus gram-positive bacteria. Infect. Immun. 71: 5803-5813. (Pubitemid 37205634)
7. Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. USA 97: 13766-13771.
8. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169: 10-14. (Pubitemid 34686113)
9. Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082. (Pubitemid 47410281)
10. Brodsky, I., and R. Medzhitov. 2007. Two modes of ligand recognition by TLRs. Cell 130: 979-981. (Pubitemid 47410282)
11. Kang, J. Y., X. Nan, M. S. Jin, S. J. Youn, Y. H. Ryu, S. Mah, S. H. Han, H. Lee, S. G. Paik, and J. O. Lee. 2009. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31: 873-884.
12. Mendrola, J. M., M. B. Berger, M. C. King, and M. A. Lemmon. 2002. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J. Biol. Chem. 277: 4704-4712. (Pubitemid 34968501)
13. Sal-Man, N., D. Gerber, I. Bloch, and Y. Shai. 2007. Specificity in transmembrane helix-helix interactions mediated by aromatic residues. J. Biol. Chem. 282: 19753-19761. (Pubitemid 47100067)
14. Zhu, F., and G. Hummer. 2010. Pore opening and closing of a pentameric ligand-gated ion channel. Proc. Natl. Acad. Sci. USA 107: 19814-19819.
15. Godfroy, J. I., III, M. Roostan, Y. S. Moroz, I. V. Korendovych, and H. Yin. 2012. Isolated Toll-like receptor transmembrane domains are capable of oligomerization. PLoS One 7: e48875.
16. Kajita, E., T. Nishiya, and S. Miwa. 2006. The transmembrane domain directs TLR9 to intracellular compartments that contain TLR3. Biochem. Biophys. Res. Commun. 343: 578-584.
17. Mouchess, M. L., N. Arpaia, G. Souza, R. Barbalat, S. E. Ewald, L. Lau, and G. M. Barton. 2011. Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation. Immunity 35: 721-732.
18. Nishiya, T., E. Kajita, and S. Miwa. 2006. Ligand-independent oligomerization of TLR4 regulated by a short hydrophobic region adjacent to the transmembrane domain. Biochem. Biophys. Res. Commun. 341: 1128-1134. (Pubitemid 43221782)
19. Papo, N., A. Braunstein, Z. Eshhar, and Y. Shai. 2004. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res. 64: 5779-5786. (Pubitemid 39095578)
20. Papo, N., D. Seger, A. Makovitzki, V. Kalchenko, Z. Eshhar, H. Degani, and Y. Shai. 2006. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res. 66: 5371-5378. (Pubitemid 43844963)
21. Cohen, T., M. Pevsner-Fischer, N. Cohen, I. R. Cohen, and Y. Shai. 2008. Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor. Biochemistry 47: 4826-4833. (Pubitemid 351555504)
22. Sackett, K., Y. Wexler-Cohen, and Y. Shai. 2006. Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J. Biol. Chem. 281: 21755-21762. (Pubitemid 44181879)
23. Rapaport, D., and Y. Shai. 1991. Interaction of fluorescently labeled pardaxin and its analogues with lipid bilayers. J. Biol. Chem. 266: 23769-23775. (Pubitemid 21908863)
24. Schneider, D., and D. M. Engelman. 2003. GALLEX, a measurement of heterologous association of transmembrane helices in a biological membrane. J. Biol. Chem. 278: 3105-3111. (Pubitemid 36801220)
25. King, G., and A. M. Dixon. 2010. Evidence for role of transmembrane helix-helix interactions in the assembly of the Class II major histocompatibility complex. Mol. Biosyst. 6: 1650-1661.
26. Dmitrova, M., G. Younès-Cauet, P. Oertel-Buchheit, D. Porte, M. Schnarr, and M. Granger-Schnarr. 1998. A new LexA-based genetic system for monitoring and analyzing protein heterodimerization in Escherichia coli. Mol. Gen. Genet. 257: 205-212.
27. Papo, N., Z. Oren, U. Pag, H. G. Sahl, and Y. Shai. 2002. The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J. Biol. Chem. 277: 33913-33921.
28. Frillingos, S., M. Sahin-Tóth, J. Wu, and H. R. Kaback. 1998. Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. FASEB J. 12: 1281-1299. (Pubitemid 28475570)
29. He, M. M., J. Sun, and H. R. Kaback. 1996. Cysteine-scanning mutagenesis of transmembrane domain XII and the flanking periplasmic loop in the lactose permease of EScherichia coli. Biochemistry 35: 12909-12914. (Pubitemid 26337346)
30. Sahin-Tóth, M., and H. R. Kaback. 1993. Cysteine scanning mutagenesis of putative transmembrane helices IX and X in the lactose permease of Escherichia coli. Protein Sci. 2: 1024-1033. (Pubitemid 23152094)
31. Kawai, T., and S. Akira. 2007. TLR signaling. Semin. Immunol. 19: 24-32. (Pubitemid 46498752)
32. Bloch, I., F. J. Quintana, D. Gerber, T. Cohen, I. R. Cohen, and Y. Shai. 2007. T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. FASEB J. 21: 393-401. (Pubitemid 46213487)
33. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17: 1-14.
34. Rosenfeld, Y., N. Papo, and Y. Shai. 2006. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides: peptide properties and plausible modes of action. J. Biol. Chem. 281: 1636-1643.
35. Rutherford, A., and R. T. Chung. 2008. Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin. Liver Dis. 28: 167-174. (Pubitemid 351632956)
36. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738. (Pubitemid 33009951)
37. Hawn, T. R., E. A. Misch, S. J. Dunstan, G. E. Thwaites, N. T. Lan, H. T. Quy, T. T. Chau, S. Rodrigues, A. Nachman, M. Janer, et al. 2007. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur. J. Immunol. 37: 2280-2289. (Pubitemid 47250219)
38. Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway, Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397. (Pubitemid 27334820)
39. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088. (Pubitemid 29001265)
40. Huang, B., J. Zhao, S. Shen, H. Li, K. L. He, G. X. Shen, L. Mayer, J. Unkeless, D. Li, Y. Yuan, et al. 2007. Listeria monocytogenes promotes tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res. 67: 4346-4352. (Pubitemid 46815083)
41. Rolls, A., R. Shechter, A. London, Y. Ziv, A. Ronen, R. Levy, and M. Schwartz. 2007. Toll-like receptors modulate adult hippocampal neurogenesis. Nat. Cell Biol. 9: 1081-1088. (Pubitemid 47338146)
42. Shi, H., M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116: 3015-3025. (Pubitemid 44684486)
43. Long, E. M., A. C. Klimowicz, H. A. Paula-Neto, B. Millen, D. M. McCafferty, P. Kubes, and S. M. Robbins. 2011. A subclass of acylated anti-inflammatory mediators usurp Toll-like receptor 2 to inhibit neutrophil recruitment through peroxisome proliferator-activated receptor γ. Proc. Natl. Acad. Sci. USA 108: 16357-16362.
44. Stewart, C. R., L. M. Stuart, K. Wilkinson, J. M. van Gils, J. Deng, A. Halle, K. J. Rayner, L. Boyer, R. Zhong, W. A. Frazier, et al. 2010. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11: 155-161.
45. West, X. Z., N. L. Malinin, A. A. Merkulova, M. Tischenko, B. A. Kerr, E. C. Borden, E. A. Podrez, R. G. Salomon, and T. V. Byzova. 2010. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467: 972-976.
46. Hashimoto, M., K. Tawaratsumida, H. Kariya, A. Kiyohara, Y. Suda, F. Krikae, T. Kirikae, and F. Götz. 2006. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J. Immunol. 177: 3162-3169. (Pubitemid 44277834)
47. Hashimoto, M., M. Furuyashiki, R. Kaseya, Y. Fukada, M. Akimaru, K. Aoyama, T. Okuno, T. Tamura, T. Kirikae, F. Kirikae, et al. 2007. Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction. Infect. Immun. 75: 1926-1932. (Pubitemid 46559462)
48. Morath, S., A. Stadelmaier, A. Geyer, R. R. Schmidt, and T. Hartung. 2002. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med. 195: 1635-1640. (Pubitemid 34666076)
49. Deininger, S., I. Figueroa-Perez, S. Sigel, A. Stadelmaier, R. R. Schmidt, T. Hartung, and S. von Aulock. 2007. Use of synthetic derivatives to determine the minimal active structure of cytokine-inducing lipoteichoic acid. Clin. Vaccine Immunol. 14: 1629-1633.
50. Pierik, M., S. Joossens, K. Van Steen, N. Van Schuerbeek, R. Vlietinck, P. Rutgeerts, and S. Vermeire. 2006. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm. Bowel Dis. 12: 1-8. (Pubitemid 43032444)
51. Hart, B. E., and R. I. Tapping. 2012. Differential trafficking of TLR1 I602S underlies host protection against pathogenic mycobacteria. J. Immunol. 189: 5347-5355.
52. Fink, A., N. Sal-Man, D. Gerber, and Y. Shai. 2012. Transmembrane domains interactions within the membrane milieu: principles, advances and challenges. Biochim. Biophys. Acta 1818: 974-983.
53. Matthews, E. E., M. Zoonens, and D. M. Engelman. 2006. Dynamic helix interactions in transmembrane signaling. Cell 127: 447-450. (Pubitemid 44647431)
54. Hennessy, E. J., A. E. Parker, and L. A. O'Neill. 2010. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9: 293-307.
55. Cohen, J. 2009. Sepsis and septic shock: inching forwards. Clin. Med. 9: 256-257.
56. Levi, M. 2008. Activated protein C in sepsis: a critical review. Curr. Opin. Hematol. 15: 481-486.
57. Alves-Filho, J. C., A. Freitas, F. O. Souto, F. Spiller, H. Paula-Neto, J. S. Silva, R. T. Gazzinelli, M. M. Teixeira, S. H. Ferreira, and F. Q. Cunha. 2009. Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis. Proc. Natl. Acad. Sci. USA 106: 4018-4023.